Compare Iris Energy Limited (IREN) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Iris Energy Limited vs BIO-TECHNE Corp — how do they compare? Iris Energy Limited trades at $35.31 (market cap $14.07B), while BIO-TECHNE Corp trades at $72.44 (market cap $11.36B). The key difference: Iris Energy Limited is the larger of the two by market cap, and BIO-TECHNE Corp pays a 0.44% dividend while Iris Energy Limited pays none. Which is the better fit depends on your goals — on Pluang, investors hold Iris Energy Limited for 28 Days and BIO-TECHNE Corp for 64 Days on average.
| IREN | TECH | |
|---|---|---|
Market Cap | $14.07B | $11.36B |
Volume | 54,492,460 | 5,390,331 |
Sector | Technology | Health |
52-Week High | $76.41 | $72.61 |
52-Week Low | $29.31 | $43.31 |
Typical Hold Time | 28 Days | 64 Days |
Enterprise Value | $16.02B | $11.39B |
Dividend Yield | — | 0.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IREN shares are trading at $35.19, down 9.05% in the last 24 hours, reflecting ongoing investor concerns despite strong analyst optimism. The stock shows bearish technical signals with key support at $33, while fundamental metrics reveal a challenging profitability picture with a negative net income margin of -99.38% despite revenue growth projections. Recent news highlights the company's aggressive pivot from Bitcoin mining to AI infrastructure, backed by multi-billion dollar contracts with Microsoft and NVIDIA.
The investment case hinges on execution of IREN's ambitious AI infrastructure expansion, with JPMorgan projecting $24 billion in annual revenue by 2030. However, significant risks include ballooning losses, high capital expenditure requirements, and intense competition in the neocloud space. Despite 80% analyst buy ratings and an $81 consensus price target suggesting 130% upside, the stock faces near-term pressure from missed earnings and negative cash flow trends.
TECH trades at $72.46, near its 52-week high of $72.70, with a slight daily decline of 0.1%. The stock shows a bullish technical signal from moving averages, while oscillators are neutral. Recent earnings have been mixed, with a Q2 2026 beat but a Q1 miss. The company maintains strong gross margins of 65.77%, though net income margin has compressed to 14.97% in 2025 from 24.6% in 2022. A significant development is the shareholder-approved acquisition by Merck KGaA at $73.00 per share, pending completion.
The pending acquisition at $73.00 offers a clear near-term upside of about 0.7% from the current price, limiting downside risk. However, execution risks remain until deal closure, and profitability pressures pose concerns for standalone operations. Analyst consensus is divided with 46% Buy and 54% Hold ratings, reflecting cautious optimism amid transition uncertainty.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Iris Energy Limited
Iris Energy is a next-generation data center company that powers Bitcoin mining and AI workloads using 100% renewable energy. It focuses on building sustainable infrastructure for the global digital economy.
Read more on IREN →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
